Daptomycin associated eosinophilic pneumonia: case report and differential diagnoses. by Basnet, Sijan et al.
Tower Health 
Scholar Commons @ Tower Health 
Reading Hospital Internal Medicine Residency Internal Medicine Residency 
6-12-2018 
Daptomycin associated eosinophilic pneumonia: case report and 
differential diagnoses. 
Sijan Basnet 
Reading Hospital-Tower Health, sijanbasnet@gmail.com 
Niranjan Tachamo 
Reading Hospital-Tower Health 
Rashmi Dhital 
Reading Hospital-Tower Health 
Biswaraj Tharu 
Maharajgunj Medical Campus, Tribhuvan University 
Follow this and additional works at: http://scholarcommons.towerhealth.org/
gme_int_med_resident_program_read 
 Part of the Internal Medicine Commons, and the Respiratory Tract Diseases Commons 
Recommended Citation 
Basnet, S., Tachamo, N., Dhital, R., & Tharu, B. (2018). Daptomycin associated eosinophilic pneumonia: 
case report and differential diagnoses.. J Community Hosp Intern Med Perspect, 8 (3), 152-155. 
https://doi.org/10.1080/20009666.2018.1475188 
This Article is brought to you for free and open access by the Internal Medicine Residency at Scholar Commons @ 
Tower Health. It has been accepted for inclusion in Reading Hospital Internal Medicine Residency by an authorized 
administrator of Scholar Commons @ Tower Health. For more information, please contact 
alexandra.short@towerhealth.org. 
CASE REPORT
Daptomycin associated eosinophilic pneumonia: case report and differential
diagnoses
Sijan Basnet a, Niranjan Tachamoa, Rashmi Dhitala and Biswaraj Tharu b
aDepartment of Medicine, Reading Hospital and Medical Center, West Reading, PA, USA; bMaharajgunj Medical Campus, Tribhuvan
University, Kathmandu, Nepal
ABSTRACT
Daptomycin is a bactericidal antibiotic approved for treatment of gram-positive skin and soft
tissue infections. We present a case of an 89-year-old man who presented with fever, short-
ness of breath and nonproductive cough on week 4 of starting daptomycin for infective
endocarditis. Computerized tomography scan showed bilateral interstitial infiltrates predomi-
nantly affecting the lower lobes. He also had peripheral eosinophilia of 6%. He was diagnosed
with eosinophilic pneumonia secondary to daptomycin use. His symptoms improved with
discontinuation of daptomycin and initiation of corticosteroids. Clinical correlation of pneu-
monia-like presentation with recent use of daptomycin should make physicians rule out this
rare adverse effect for early institution of correct treatment.
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1. Introduction
Daptomycin is a lipopeptide antibiotic approved by
the Food and Drug Administration (FDA) for treat-
ment of skin and soft tissue infections by
Staphylococcus aureus (methicillin-susceptible or
resistant strains), Streptococcus species and vancomy-
cin-susceptible Enterococcus faecalis [1,2] Use of dap-
tomycin has been increasing recently as an effective
treatment alternative to vancomycin [3].
Subsequently, rare adverse effects like eosinophilic
pneumonia are being reported more frequently.
Daptomycin associated eosinophilic pneumonia
(DAEP), although rare, can mimic other pneumonia
resulting in delayed diagnosis and management, and
hence has the potential to cause serious morbidity
and mortality [1].
2. Case description
An 89-year-old man presented to the emergency
department (ED) with a history of fever, nonproductive
cough and exertional shortness of breath for a few days.
He was started 4 weeks previously on intravenous dap-
tomycin for 6 weeks for coagulase-negative staphylo-
coccal bacteremia and infective endocarditis of mitral
valve following a urinary procedure. Daptomycin was
chosen in this patient for once daily dosing. He was a
nonsmoker with no history of chronic obstructive pul-
monary disease or asthma. In the ED, he was afebrile
(temperature 99.8°F) with a heart rate of 77 bpm, blood
pressure of 129/74 mm Hg and respiratory rate of 29
breaths per minute. His initial oxygen saturation was
72% on room air and required high flow oxygen to
maintain his oxygen saturation. Chest examination
revealed vesicular breath sounds with diffuse rales.
Cardiac auscultation was normal. The rest of the phy-
sical examination was unremarkable.
Pertinent labs included white count of 7900/µl
with peripheral eosinophilia of 6% (reference range:
0.0–6.0%), Eosinophil count 500/µl (reference range:
150–300/uL), C-reactive protein 27.95 mg/dL (refer-
ence range: <1.00 mg/dL), erythrocyte sedimentation
rate 54 mm/h (reference range: 0–15 mm/h) and
brain natriuretic peptide 102 pg/mL (reference
range: 0–100 pg/mL). Electrocardiogram was unre-
markable. Chest X-ray demonstrated hazy bilateral
airspace opacification predominantly in the lower
lobes. Computerized tomography (CT) scan of the
chest revealed bilateral lower lobe ground-glass opa-
cification with interlobular septal thickening
(Figure 1). Streptococcus pneumoniae and Legionella
urinary antigens were negative. ANA, Rheumatoid
factor, ANCA and respiratory pathogen panel were
negative. Patient lives in Pennsylvania and denied
travel outside the USA. Stool ova and parasites done
were negative. Urine drug screen was not done but
patient denied substance abuse. He was not on any
over the counter pain medications. Blood and urine
cultures done during hospital stay were negative.
With concern for DAEP, daptomycin was discon-
tinued. Intravenous methylprednisolone at 60 mg
every 6 h was started. Daptomycin was switched to
intravenous vancomycin to complete the 6-week anti-
biotic course for infective endocarditis. He was also
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started on intravenous cefepime and metronidazole
(2-week course) for broad-spectrum coverage of
pneumonia. Resolution of eosinophilia (0.8%) with
the appearance of neutrophilic leucocytosis (92.3%
neutrophils with WBC of 12,500/µl) were noted.
With improvement of his respiratory status,
his methylprednisolone was stopped, and he was
started on prednisone taper for 6 weeks. He was
also started on prophylactic sulfamethoxazole-tri-
methoprim 800/160 mg two times daily until his
prednisone would drop down to 20 mg daily. High
flow oxygen was weaned off to nasal cannula oxygen.
Repeat CT chest (Figure 2) 2 weeks later revealed
partial clearing of the diffuse ground-glass opacities. His
respiratory status had improved, and he was maintaining
saturation in low 90s on 2–3-L oxygen via nasal cannula.
He was discharged home on prednisone taper, prophy-
lactic sulfamethoxazole-trimethoprim, and supplemental
oxygen. Unfortunately, he was lost to follow-up.
3. Discussion
DAEP was first reported in 2007. DAEP is charac-
terized by eosinophilic infiltration of the lung par-
enchyma ranging from asymptomatic infiltrates to
acute respiratory distress syndrome necessitating
mechanical ventilation [4]. It is believed that par-
enchymal damage secondary to destruction of
Figure 1. CT scan of chest showing bilateral diffuse ground glass opacity of lung parenchyma on presentation.
Figure 2. CT scan of chest showing improved opacity of lung parenchyma 2 weeks after discontinuation of daptomycin.
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pulmonary surfactant and induction of allergic reac-
tion by daptomycin causes DAEP [4–7].
DAEP is characteristically seen in elderly males and
usually manifests as a febrile illness lasting a few weeks
and is accompanied by constitutional symptoms, dys-
pnea and nonproductive cough [4,8]. Kim et al devel-
oped a case definition for DAEP and classified it as
definite, probable, possible and unlikely based on ful-
fillment of criteria. Diagnosis is ‘definite’ if there is a
history of exposure to daptomycin, fever, dyspnea
requiring oxygen or mechanical ventilation, pulmon-
ary infiltrates identified on chest X-ray or CT scan,
bronchoalveolar lavage (BAL) with >25% eosinophils
and clinical improvement with discontinuation of dap-
tomycin. Diagnosis is ‘probable’ if there is a history of
daptomycin exposure, dyspnea requiring oxygen or
mechanical ventilation, pulmonary infiltrates identified
on chest X-ray or CT scan, peripheral eosinophilia and
clinical improvement following daptomycin withdra-
wal [4], as in our case. We did not do a bronchoscopy
as our patient was frail. Initial diagnostic studies may
show hypoxemia, infiltrates on chest imaging and vari-
ably, peripheral eosinophilia [4]. Pulmonary eosino-
philic infiltrates or BAL eosinophilia is a cornerstone
for diagnosis [2,9]. Discontinuation of daptomycin
with or without corticosteroid is the mainstay of man-
agement [4,8]. Corticosteroid is believed to rapidly
reverse the inflammation and thereby improve the
hypoxia [8]. Patients are usually started on intravenous
methylprednisone 60–125 mg every 6–8 h, transitioned
to oral prednisone 40–60 mg daily with clinical
improvement and is tapered over 2–6 weeks to avoid
relapse [8,10].
4. Differential diagnosis
Conditions that can have a similar presentation of
dyspnea and bilateral ground glass pulmonary infil-
trates include pneumonia, hypersensitivity pneumo-
nitis, alveolar proteinosis and cryptogenic organizing
pneumonia. The patient did not have constitutional
symptoms, sputum production with negative pneu-
mococcal and Legionella urinary antigens making
pneumonia unlikely. Pneumocystis jirovecii pneumo-
nia without constitutional symptoms, history of expo-
sure to HIV or high-risk behavior can be ruled out.
Alveolar proteinosis is a rare diagnosis which is
uncommon with no history of smoking. Lastly, cryp-
togenic organizing pneumonia is characteristically
associated with a change in location of consolidation
which was absent in our patient on serial imaging.
5. Conclusion
DAEP is an uncommonly observed adverse effect of
daptomycin. Its incidence will increase with increas-
ing use of daptomycin. Clinicians must be aware of
this adverse effect and presentation for early discon-
tinuation of the medication and institution of
corticosteroids.
Key points
(1) Eosinophilic pneumonia is a rare side effect of
daptomycin.
(2) It presents as febrile illness, nonproductive
cough and shortness of breath within a few
weeks of initiation of daptomycin.
(3) Diagnosis is ‘definite’ if there is a history of
exposure to daptomycin, fever, dyspnea
requiring oxygen or mechanical ventilation,
pulmonary infiltrates identified on chest
X-ray or CT scan, bronchoalveolar lavage
(BAL) with >25% eosinophils and clinical
improvement with discontinuation of
daptomycin.
(4) Discontinuation of daptomycin and corticos-
teroids are the primary treatment measures.
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